

Special Issue

Vaccines Against Influenza and Other Respiratory Virus Infections

Message from the Guest Editor

Respiratory viral infections represent significant global health challenges, causing millions of illnesses and deaths each year. Vaccines are crucial in preventing these infections by eliciting specific immune responses, including mucosal immunity, antibody production, and T-cell responses. Despite significant advancements in vaccine development for respiratory viral infections, several challenges remain. These include addressing the high mutation rates of the viruses, promoting cross-protective and long-lasting immunity, ensuring effective mucosal immunity in the respiratory tract, providing adequate protection for high-risk populations, and minimizing potential adverse effects associated with the vaccines. This issue aims at highlighting recent advancements in developing and testing vaccines against influenza and other respiratory viral infections. We welcome the submission of original research and review articles which focus on the following topics:

- Vaccine development.
- Adjuvants or vaccine delivery platforms.
- Vaccine-induced immune responses.
- Immunogenicity, protective efficacy of vaccines in high-risk groups.
- Adverse reactions, long-term safety profiles of vaccines.

Guest Editor

Dr. Santosh Dhakal

Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, 1800 Denison Avenue, Manhattan, KS 66506, USA

Deadline for manuscript submissions

20 October 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/235714

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).